精神分裂症与双相障碍多基因风险评分用于识别精神病性障碍
该研究利用精神分裂症与双相障碍多基因风险评分,在1168例精神病性障碍患者、552名未患病亲属及1472名对照中评估其区分能力。结果显示患者及亲属的风险评分均升高,但预测模型准确性有限。作者认为多基因风险评分尚不适用于临床,未来优化后或可辅助风险降低建议与早期干预。
要点
- 精神病性障碍患者的精神分裂症与双相障碍多基因风险评分均显著升高。
- 未患病亲属的多基因风险评分亦升高,但幅度低于患者。
- 多基因风险评分预测模型准确性有限,尚不适用于临床。
核心结论
- 精神分裂症与双相障碍多基因风险评分可区分 broadly defined psychosis 患者及其未患病亲属与对照,但预测模型准确性有限,尚不适用于临床。
研究设计与样本
- 利用精神分裂症与双相障碍多基因风险评分,在1168例精神病性障碍患者、552名未患病亲属及1472名对照中评估其区分能力。
主要发现
- 精神病性障碍患者的精神分裂症与双相障碍多基因风险评分均大幅升高。
- 未患病亲属的多基因风险评分亦升高,但程度较低。
- 预测模型的准确性有限。
临床怎么用
- 多基因风险评分目前不推荐用于临床实践。
- 未来评分优化后或可用于风险降低建议与精神病早期干预。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is increasing evidence for shared genetic susceptibility between schizophrenia and bipolar disorder. Although genetic variants only convey subtle increases in risk individually, their combination into a polygenic risk score constitutes a strong disease predictor.AimsTo investigate whether schizophrenia and bipolar disorder polygenic risk scores can distinguish people with broadly defined psychosis and their unaffected relatives from controls. METHOD: Using the latest Psychiatric Genomics Consortium data, we calculated schizophrenia and bipolar disorder polygenic risk scores for 1168 people with psychosis, 552 unaffected relatives and 1472 controls. RESULTS: Patients with broadly defined psychosis had dramatic increases in schizophrenia and bipolar polygenic risk scores, as did their relatives, albeit to a lesser degree. However, the accuracy of predictive models was modest. CONCLUSIONS: Although polygenic risk scores are not ready for clinical use, it is hoped that as they are refined they could help towards risk reduction advice and early interventions for psychosis.Declaration of interestR.M.M. has received honoraria for lectures from Janssen, Lundbeck, Lilly, Otsuka and Sunovian.
引用
- Calafato MS, Thygesen JH, Ranlund S, et al. Use of schizophrenia and bipolar disorder polygenic risk scores to identify psychotic disorders. Br J Psychiatry. 2018. PMID: 30113282. doi:10.1192/bjp.2018.89
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。